Atypical pharmacokinetics of atazanavir in an HIV-1-infected patient

被引：4

作者：

Cattaneo, Dario ^{[1
]}

Meraviglia, Paola ^{[2
]}

Cozzi, Valeria ^{[1
]}

Baldelli, Sara ^{[1
]}

Milani, Greta ^{[1
]}

Clementi, Emilio ^{[1
,3
]}

机构：

[1] Univ Milan, Luigi Sacco Univ Hosp, Clin Pharmacol Unit, Milan, Italy

[2] Univ Milan, Luigi Sacco Univ Hosp, Div Infect Dis 2, Milan, Italy

[3] E Medea Sci Inst, Bosisio Parini, Italy

来源：

FUNDAMENTAL & CLINICAL PHARMACOLOGY | 2012年 / 26卷 / 02期

关键词：

HAART; HIV; pharmacogenetics; pharmacokinetics; therapeutic drug monitoring; PLASMA-CONCENTRATIONS; INFECTED PATIENTS; EFFICACY;

D O I：

10.1111/j.1472-8206.2010.00905.x

中图分类号：

R9 [药学];

学科分类号：

1007 ;

摘要：

An HIV-infected patient with very low atazanavir (ATV) plasma trough concentrations despite clinical signs of poor drug tolerability was described. By therapeutic drug monitoring (TDM), the authors found that the patient had an atypical ATV pharmacokinetics characterized by rapid drug absorption followed by very fast drug clearance probably attributable to his genetic background. This case underlines the importance of traditional and pharmacogenetic-based TDM for the individualization of ATV therapy in HIV-1 patients.

引用

页码：204 / 206

页数：3

共 50 条

[1] Pharmacokinetics of the combination raltegravir/atazanavir in HIV-1-infected patients
Jansen, A.
Colbers, E. P. H.
van der Ven, A. J. A. M.
Richter, C.
Rockstroh, J. K.
Wasmuth, J. C.
van Luin, M.
Burger, D. M.
HIV MEDICINE, 2013, 14 (07) : 449 - 452
[2] Population pharmacokinetics of atazanavir/ritonavir in HIV-1-infected children and adolescents
Foissac, Frantz
Blanche, Stephane
Dollfus, Catherine
Hirt, Deborah
Firtion, Ghislaine
Laurent, Corinne
Treluyer, Jean-Marc
Urien, Saik
BRITISH JOURNAL OF CLINICAL PHARMACOLOGY, 2011, 72 (06) : 940 - 947
[3] Sialolithiasis in an HIV-1-infected patient treated with atazanavir/ritonavir monotherapy
Le, Minh P.
Stitou, Hind
Soulie, Cathia
Katlama, Christine
Peytavin, Gilles
JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2013, 68 (03) : 727 - 729
[4] Exposure-Related Effects of Atazanavir on the Pharmacokinetics of Raltegravir in HIV-1-Infected Patients
Cattaneo, Dario
Ripamonti, Diego
Baldelli, Sara
Cozzi, Valeria
Conti, Francesca
Clementi, Emilio
THERAPEUTIC DRUG MONITORING, 2010, 32 (06) : 782 - 786
[5] Disappearance of Renal Stones in an HIV-1-Infected Patient After Reduction of Atazanavir Dose
Lanzafame, Massimiliano
Bonora, Stefano
Lattuada, Emanuela
Calcagno, Andrea
Di Perri, Giovanni
Concia, Ercole
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2014, 30 (09) : 835 - 836
[6] The pharmacokinetics of nelfinavir in HIV-1-infected children
van Heeswijk, RPG
Scherpbier, HJ
de Koning, LA
Heymans, HSA
Lange, JMA
Beijnen, JH
Hoetelmans, RMW
THERAPEUTIC DRUG MONITORING, 2002, 24 (04) : 487 - 491
[7] Atazanavir approved for treatment-naive HIV-1-infected adults
不详
BRITISH JOURNAL OF HOSPITAL MEDICINE, 2009, 70 (01) : 8 - 8
[8] Pharmacokinetics and Pharmacodynamics of Atazanavir in HIV-1-Infected Children Treated With Atazanavir Powder and Ritonavir: Combined Analysis of the PRINCE-1 and-2 Studies
Sevinsky, Heather
Zaru, Luna
Wang, Reena
Xu, Xiaohui
Pikora, Cheryl
Correll, Todd A.
Eley, Timothy
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2018, 37 (06) : E157 - E165
[9] Effects of hepatitis C virus infection on the pharmacokinetics of ritonavir-boosted atazanavir in HIV-1-infected patients
Di Biagio, Antonio
Rosso, Raffaella
Loregian, Arianna
Pagni, Silvana
Sormani, Maria Pia
Cenderello, Giovanni
Palu, Giorgio
Viscoli, Claudio
JOURNAL OF INFECTION AND CHEMOTHERAPY, 2012, 18 (04) : 587 - 590
[10] Pharmacokinetics of antiretroviral therapy in HIV-1-infected children
Fraaij, PLA
van Kampen, JJA
Burger, DM
de Groot, R
CLINICAL PHARMACOKINETICS, 2005, 44 (09) : 935 - 956

← 1 2 3 4 5 →